Entellus Medical Inc., a Maple Grove, MN-based medical device company that markets minimally invasive solutions for treatment of patients with chronic sinusitis, completed a $35m round of funding.
The round was led by Covidien Ventures, with participation from existing investors SV Life Sciences, Essex Woodlands, Split Rock Partners, and Greenspring Associates.
The company intends to use the funds for ongoing operations and commercialization of its multiple product lines, which are used by Ear, Nose, & Throat (ENT) physicians to dilate narrowed or obstructed sinus drainage pathways.
Led by President and CEO Brian Farley, Entellus’ product lines include:
– the XprESS multi-sinus dilation tool, which offers ENT physicians a, cost-effective tool to trans-nasally treat the frontal, sphenoid or maxillary sinuses in either a doctor’s office or operating room;
– the FinESS product line, which is designed for use in a doctor’s office and enables ENT physicians to directly visualize and dilate the drainage path from the maxillary sinus.